Premium
Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel?
Author(s) -
Stahl Maximilian,
Zeidan Amer M.
Publication year - 2017
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.30532
Subject(s) - medicine , histone deacetylase , hypomethylating agent , histone deacetylase inhibitor , myelodysplastic syndromes , clinical trial , pharmacology , cancer research , histone , genetics , dna methylation , biology , gene , bone marrow , gene expression
The combination of hypomethylating agents and histone deacetylase inhibitors demonstrates promising results in phase 1 trials but unfortunately disappointing results in all phase 2 trials to date. See also pages 994‐1002.